Aeglea Biotherapeutic

805 Las Cimas Parkway, Suite 100
Austin,  TX  78746

United States
https://www.aegleabio.com/

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and other high burden diseases. Aeglea’s lead product candidate, pegzilarginase, is being investigated for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation.

 Corporate, Product or Service Images

• Title: Arginase-1 Deficiency (ARG1-D) Masquerading as Hereditary Spastic Paraplegia: Implications for Diagnostic Testing (Nov 25, 2020)
  https://ir.aegleabio.com/static-files/cc0e3ece-6b08-4cc3-a6a5-2d169c1d9bb4

• 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D) (Nov 30, 2020)
  https://ir.aegleabio.com/static-files/9ac46959-2bd4-4605-a0e3-a714f56bd244

• Aeglea Company Presentation (Nov 30, 2020)
  https://ir.aegleabio.com/static-files/213bfa5a-5be9-47c2-8915-d72afb55051f